NO20071160L - Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency - Google Patents

Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency

Info

Publication number
NO20071160L
NO20071160L NO20071160A NO20071160A NO20071160L NO 20071160 L NO20071160 L NO 20071160L NO 20071160 A NO20071160 A NO 20071160A NO 20071160 A NO20071160 A NO 20071160A NO 20071160 L NO20071160 L NO 20071160L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
androgen deficiency
estrogen receptor
receptor modulator
selective estrogen
Prior art date
Application number
NO20071160A
Other languages
Norwegian (no)
Inventor
Risto Lammintausta
Taru Blom
Janne Komi
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/en
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20071160L publication Critical patent/NO20071160L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av en selektiv østrogenreseptormodulator, eller en isomer, isomerblanding, metabolitt eller et farmasøytisk akseptabelt salt derav for fremstilling av et farmasøytisk preparat for anvendelse i en fremgangsmåte for behandling eller forebygging av androgenmangel eller sykdommer og forstyrrelser forårsaket av androgenmangel hos et mannlig individ.The present invention relates to the use of a selective estrogen receptor modulator, or an isomer, isomer composition, metabolite or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for use in a method of treating or preventing androgen deficiency or diseases and disorders caused by a male androgen deficiency. .

NO20071160A 2004-09-03 2007-03-01 Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency NO20071160L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (en) 2004-09-21 2004-09-21 A method of treating or preventing an androgen deficiency
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (1)

Publication Number Publication Date
NO20071160L true NO20071160L (en) 2007-05-25

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071160A NO20071160L (en) 2004-09-03 2007-03-01 Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency

Country Status (10)

Country Link
EP (1) EP1786408A4 (en)
JP (1) JP2008511615A (en)
KR (1) KR20070059110A (en)
AU (1) AU2005279178A1 (en)
BR (1) BRPI0514701A (en)
CA (1) CA2578852A1 (en)
MX (1) MX2007002606A (en)
NO (1) NO20071160L (en)
RU (1) RU2007112114A (en)
WO (1) WO2006024689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363344B2 (en) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド Process for the preparation of triphenylbutene derivatives useful for therapy
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9975832B2 (en) 2014-12-29 2018-05-22 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (en) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
JP2003534375A (en) * 2000-05-26 2003-11-18 フィッチ，ハリー Treatment of androgen deficiency in men with selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ES2319785T3 (en) * 2001-11-29 2009-05-12 Gtx, Inc. PREVENTION AND TREATMENT OF OSTEOPOROSIS INDUCED BY ANDROGEN PRIVACY.

Also Published As

Publication number Publication date
MX2007002606A (en) 2007-05-15
AU2005279178A1 (en) 2006-03-09
EP1786408A4 (en) 2010-07-28
EP1786408A1 (en) 2007-05-23
JP2008511615A (en) 2008-04-17
BRPI0514701A (en) 2008-06-24
CA2578852A1 (en) 2006-03-09
WO2006024689A1 (en) 2006-03-09
KR20070059110A (en) 2007-06-11
RU2007112114A (en) 2008-10-10

Similar Documents

Publication Publication Date Title
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
NO20071160L (en) Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency
MA32200B1 (en) New formulations, tablets consisting of these formulas, their use and method of preparation
WO2009068689A3 (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
NO20072352L (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20075660L (en) Composition for the treatment of inflammatory diseases
MX2009001711A (en) Sustained-release formulations of topiramate.
ATE453642T1 (en) SUBSTITUTED PHENYLAMINOPYRIMIDINES
EA201100062A1 (en) CONNECTIONS AND METHODS OF MODELING RECEPTORS ASSOCIATED WITH PROTEIN G
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
NO20092584L (en) Pharmaceutical compositions and their methods of use
MX2010004494A (en) Use of trkb antibodies for the treatment of respiratory disorders.
EP2178870A4 (en) Indole and indazole compounds as an inhibitor of cellular necrosis
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2014170755A3 (en) Sustained-release formulations of colchicine and methods of using same
NO20100301L (en) Improved brimonidine compositions for the treatment of erythema
WO2006119389A3 (en) Quinine-containing controlled-release formulations
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2007038506A3 (en) Method for the treatment of cachexia
NO20083836L (en) N hydroksyakrylamidforbindelser
NO20080936L (en) Transdermal drug delivery devices containing O-desmethylvenlafaxine (ODV) or salts thereof
DK1784173T3 (en) Pharmaceutical composition for the prevention and treatment of metabolic bone disorders containing alpha-arylmethoxyacrylate derivatives
EA201171035A1 (en) COMPOSITIONS, INCLUDING MODULATORS PDE4, AND METHOD OF THEIR APPLICATION FOR THE TREATMENT, PREVENTION AND SUPPORT OF TUBERCULOSIS
WO2011047837A3 (en) Melt-granulated cinacalcet
WO2005077124A3 (en) Compounds and compositions as lxr modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application